Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · IEX Real-Time Price · USD
10.17
-0.37 (-3.51%)
Apr 25, 2024, 4:00 PM EDT - Market closed
Amicus Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Amicus Therapeutics stock have an average target of 19, with a low estimate of 15 and a high estimate of 22. The average target predicts an increase of 86.82% from the current stock price of 10.17.
Analyst Consensus: Buy
* Price targets were last updated on Mar 18, 2024.
Analyst Ratings
The average analyst rating for FOLD stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 2 | 1 | 0 |
| Buy | 1 | 2 | 2 | 3 | 3 | 3 |
| Hold | 2 | 2 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 7 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $21 → $19 | Buy | Maintains | $21 → $19 | +86.82% | Mar 18, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $22 | Buy | Reiterates | $22 | +116.32% | Feb 29, 2024 |
| Morgan Stanley | Morgan Stanley | Hold → Buy Upgrades $15 → $20 | Hold → Buy | Upgrades | $15 → $20 | +96.66% | Dec 19, 2023 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $14 → $15 | Hold | Maintains | $14 → $15 | +47.49% | Nov 9, 2023 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $15 → $14 | Hold | Maintains | $15 → $14 | +37.66% | Oct 10, 2023 |
Financial Forecast
Revenue This Year
541.82M
from 399.36M
Increased by 35.67%
Revenue Next Year
695.70M
from 541.82M
Increased by 28.40%
EPS This Year
0.00
from -0.51
EPS Next Year
0.40
from 0.00
Increased by 8,809.01%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 575.9M | 838.2M | 1.1B | 1.3B | 1.5B |
| Avg | 541.8M | 695.7M | 969.4M | 1.2B | 1.4B |
| Low | 500.8M | 606.6M | 853.0M | 1.1B | 1.3B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 44.2% | 54.7% | 54.7% | 30.8% | 29.2% |
| Avg | 35.7% | 28.4% | 39.3% | 21.2% | 20.1% |
| Low | 25.4% | 12.0% | 22.6% | 10.9% | 10.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.19 | 0.65 | 1.20 | 2.11 | 2.91 |
| Avg | 0.00 | 0.40 | 1.11 | 1.73 | 2.40 |
| Low | -0.09 | 0.17 | 1.04 | 1.36 | 1.89 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 14,274.7% | 196.7% | 89.4% | 67.7% |
| Avg | - | 8,809.0% | 176.2% | 55.6% | 38.2% |
| Low | - | 3,578.7% | 157.5% | 22.2% | 9.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.